Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

Abstract Background Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb‐Plt‐PEM) in nonsquamous non‐small cell lung cancer (non‐sq NSCLC) are unclear. We investigated the Glasgow Prognostic (GP) score, neutrophil‐to‐lymphocyte ratio (NLR), and body...

Full description

Bibliographic Details
Main Authors: Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi, Takashi Osaki, Yosuke Miura, Yukihiro Umeda, Akihiro Ono, Hiroyuki Minemura, Yutaka Yamada, Junichi Nakagawa, Yuki Kozu, Hirokazu Taniguchi, Hiromitsu Ohta, Takashi Kasai, Kyoichi Kaira, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Thoracic Cancer
Subjects:
body mass index
immune checkpoint inhibitors
neutrophil‐to‐lymphocyte ratio
nonsquamous non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.15036

Internet

https://doi.org/10.1111/1759-7714.15036

Similar Items